The Law Commission's new consultation could make software and AI more explicitly subject to product-liability rules and address obstacles to proving a claim. It has not changed the law. Opened on 8 October 2026, with responses due by 14 January 2027, the project offers a reform discussion, not a new compensation entitlement for every healthcare-AI error. The Commission's project page sets out that timetable.
Start with the correct jurisdiction and status
This article is dated 10 October 2026. Although the debate is relevant across UK healthcare, the Law Commission of England and Wales states that its reform recommendations apply to England and Wales. Its consultation summary separately recognises the existing Act's wider territorial application. Readers should not treat a headline about a UK consultation as a uniform new legal regime across all four nations.
The proposals are provisional. The project anticipates a later final report and recommendations, after considering responses. Even a final recommendation is not equivalent to legislation having taken effect. Healthcare organisations should continue to work within their current obligations while considering how the proposals might affect future contracts, evidence and risk allocation.
The analysis below is general information, not advice on an individual claim. An actual incident needs jurisdiction-specific legal, indemnity and organisational advice, alongside immediate attention to the patient's care.
Current position versus proposed reform
The following distinction is based on the Commission's October 2026 project material and consultation paper. It summarises the questions relevant to healthcare rather than reproducing the complete proposals.
| Issue | Current position or difficulty identified | Proposed direction, not enacted law |
|---|---|---|
| Digital products | Uncertainty about applying an older product framework to digital supply | Explicit inclusion of software and AI within a broader product definition |
| Supply and modification | Digital delivery and later alteration complicate the analysis | Clearer treatment of digital supply and substantial modification |
| Responsible parties | Modern supply chains can make responsibility difficult to locate | Additional potentially liable categories |
| Evidence | Technical complexity may make defect and causation hard to establish | Mechanisms addressing exceptional evidential difficulty |
| Defect | Disputes about the safety people are entitled to expect | A more structured framework for assessing defect |
None of these proposals should be paraphrased as "developers will pay whenever AI is wrong". Defect, harm, causal questions, applicable defences and the identity of the relevant parties remain important.
A clinical mistake and a defective product are not identical concepts
Imagine a fictional patient whose follow-up is delayed after an AI-assisted system marks an unresolved action as complete. Several different explanations are possible. The original software may have behaved incorrectly. An integration may have mapped a status field wrongly. A local policy may have assigned no owner to failed transactions. A professional may have overlooked a clear warning.
Those possibilities are not mutually exclusive, and the example does not determine liability. Its purpose is to show why a product-liability analysis should not begin and end with the clinician whose name appears on the final record.
The GMC's current AI resource, checked on 10 October 2026, distinguishes clinicians' responsibility for their decisions from the responsibilities of people involved in creating, testing and updating technology. That is a professional-accountability statement. It does not itself allocate civil liability or decide whether a particular compensation claim succeeds.
For a hospital board, the practical question is therefore how to make the separate roles visible. Who selected the product? Who configured the connection? Who approved the use? Who reviewed the output? Who controlled a later update? A system that cannot answer those questions makes both improvement and investigation harder.
Why changes after deployment deserve attention
The consultation's discussion of substantial modification is relevant to a market in which a clinical tool may evolve after procurement. The same product name might sit over a different model, retrieval source set or set of permissions. Whether a particular alteration would meet a legal threshold is a matter for detailed analysis, not an assumption this article can settle.
As a proposed organisational safeguard, keep an evidence-to-version register. Record the evaluated configuration, the functions authorised locally and the supplier's responsibilities for notifying material changes. If a model update changes how incomplete information is handled, a service should be able to identify whether the supporting evidence still applies.
This does not require freezing a product indefinitely. Security patches and beneficial improvements can be important. The aim is to make change governable, so that an organisation can distinguish ordinary maintenance from a change that undermines the assumptions behind its original decision.
The evidence problem starts before a dispute
A later investigation might need the source input, the output seen by the user, the product version, relevant system acknowledgements and the final action. That does not justify retaining every patient conversation forever or copying sensitive material into personal accounts.
A sensible proposal is to agree evidence requirements before use with clinical safety, legal and information-governance teams. Separate the care record from technical logs and from any material retained specifically for an investigation. Specify who can preserve it, who can inspect it and how unnecessary duplication is avoided.
The ICO's AI data-minimisation guidance, checked on 10 October 2026, addresses retention at both training and inference stages. That makes a useful counterweight to an indiscriminate "keep everything for legal reasons" approach. A justified audit trail should have a defined purpose and handling arrangement.
What a useful healthcare consultation response could contribute
A clinical organisation can contribute practical examples without claiming that reform alone will solve implementation risk. It could describe a case where an output cannot be reconstructed after an update, a contract that does not identify which party controls a critical component, or a record that obscures whether an action was proposed or actually completed.
For each example, explain the obstacle rather than simply requesting that another party bear the cost. What information was unavailable? Who controlled it? What evidence would help distinguish a product defect from a deployment failure? Could the same requirement be met without unnecessary retention of patient information?
The official consultation response page provides the process. As at 10 October 2026, submissions are part of an active consultation, not a mechanism for determining an individual patient's compensation.
What clinicians should do now
The immediate response is not to stop using all AI or assume that future reform will transfer responsibility away from the clinic. Use approved workflows, understand their boundaries, preserve proportionate records and raise concerns when a system's behaviour or deployment appears unsafe.
For professional learning, iatroX's October 2026 CPD workflow can help organise a reviewed learning record about a genuine knowledge gap. Such a record is neither legal protection nor proof of competence to approve an AI system. Its value is in documenting what was examined, what the clinician understood and what should change in practice.
A better liability framework may improve access to redress. Safer healthcare still requires the separate work of preventing foreseeable errors, discovering failures promptly and ensuring someone can correct their consequences.
Frequently asked questions
Has the October 2026 consultation changed healthcare-AI liability law?
No. As at 10 October 2026, these are provisional proposals under consultation, not enacted reforms.
Does the consultation apply uniformly across the UK?
The Law Commission of England and Wales states that its recommendations apply to England and Wales. The territorial position of existing legislation and any eventual reforms must be considered separately.
Would explicit software liability mean doctors are no longer accountable?
No. Product liability, organisational responsibilities and clinicians' professional obligations are different questions; the relevant facts and law determine how they interact.
Turn a genuine professional learning need into a reviewed CPD record →